AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10090432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 2916
Study 10090432 — intervention group
Group type: COMPARATOR
Intervention: Comparator therapies
Number of subjects: 2916
Study 7727835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17‐propionate preparation under occlusion
Number of subjects: 20
Study 7727835 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticoid‐free cream under occlusion
Number of subjects: 20
Study 7727835 — intervention group
Group type: COMPARATOR
Intervention: No treatment and occlusion (aluminium chamber)
Number of subjects: 20
Study 7727835 — intervention group
Group type: COMPARATOR
Intervention: No treatment and no occlusion
Number of subjects: 20
Study 2029832 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12
Study 2029832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6873608 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (6 mg at 5 h and at 30 min before the meal)
Number of subjects: 20
Study 6873608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31725909 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contraction testing
Number of subjects: 0
Study 31725909 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0
Study 29718418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling + exercise
Number of subjects: 61
Study 29718418 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 61
Study 27385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg) with fixed dose of diuretics
Number of subjects: 44
Study 27385022 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan (15 mg) with half-dose of diuretics
Number of subjects: 44
Study 27385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tolvaptan with fixed dose and half-dose of diuretics)
Number of subjects: 44
Study 26912557 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus standard of care (SOC)
Number of subjects: 921
Study 26912557 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 921
Study 24680848 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 1: preconditioning with cathodal tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15
Study 24680848 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2: preconditioning with anodal tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15
Study 24680848 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3: sham tDCS over the left M1 followed by 10 Hz rTMS over the right M1
Number of subjects: 15
Study 24680848 — intervention group
Group type: COMPARATOR
Intervention: Condition 4: sham tDCS over the left M1 followed by sham rTMS over the right M1
Number of subjects: 15
Study 18828899 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-1 (sulphadoxine-pyrimethamine)
Number of subjects: 0
Study 18828899 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-2 (sulphadoxine-pyrimethamine)
Number of subjects: 0
Study 18828899 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-3 (sulphadoxine-pyrimethamine)
Number of subjects: 0
Study 15194017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 10 mg
Number of subjects: 710
Study 15194017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 20 mg
Number of subjects: 710
Study 15194017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin 40 mg
Number of subjects: 710
Study 15194017 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 710
Study 11001754 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance trained
Number of subjects: 29
Study 9311407 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 2.1 ml/h (low rate group)
Number of subjects: 24
Study 9311407 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of buprenorphine (0.017 mg/h) with 2% lignocaine at 6.3 ml/h (high rate group)
Number of subjects: 24
Study 7506178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 50 mg/dose
Number of subjects: 70
Study 7506178 — intervention group
Group type: COMPARATOR
Intervention: Lysine-acetylsalicylate 720 mg/dose
Number of subjects: 70
Study 2882339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (subcutaneous calcium heparin, 12,500 IU daily)
Number of subjects: 728
Study 2882339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 728
Study 2882339 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual therapy)
Number of subjects: 728
Study 30932953 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 3438
Study 30932953 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART initiation
Number of subjects: 3438
Study 28581346 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral therapy group program - 'Recapture Life'
Number of subjects: 39
Study 26702595 — intervention group
Group type: COMPARATOR
Intervention: Matched hydration (MHG)
Number of subjects: 133
Study 25080942 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmatic preconception care (PCC)
Number of subjects: 0
Study 25080942 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antenatal risk assessment
Number of subjects: 0
Study 25080942 — intervention group
Group type: COMPARATOR
Intervention: Control group (municipalities not receiving interventions)
Number of subjects: 0
Study 22836851 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS technique
Number of subjects: 60
Study 22836851 — intervention group
Group type: COMPARATOR
Intervention: Customary presentations
Number of subjects: 60
Study 19738402 — intervention group
Group type: EXPERIMENTAL
Intervention: ERASE Stress Sri Lanka (ES-SL)
Number of subjects: 166
Study 19738402 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) religious class
Number of subjects: 166
Study 17368248 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intracervical anesthesia
Number of subjects: 84
Study 17368248 — intervention group
Group type: COMPARATOR
Intervention: Combined local and paracervical anesthesia
Number of subjects: 84
Study 15548777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 2-MHz transcranial Doppler ultrasonography
Number of subjects: 126
Study 15548777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 11672452 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based unsupervised exercise training programme of moderate intensity
Number of subjects: 9
Study 11672452 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control period
Number of subjects: 9
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m. (OME20)
Number of subjects: 1154
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg o.m. (OME10)
Number of subjects: 1154
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d. (RAN)
Number of subjects: 1154
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg weekends (OMEW)
Number of subjects: 1154
Study 9218069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 1154
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox's regression analysis
Number of subjects: 1154
Study 9218069 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic relapse
Number of subjects: 1154
Study 8034405 — intervention group
Group type: EXPERIMENTAL
Intervention: ComputerLink (nurse-supervised information, decision support, and communication services)
Number of subjects: 26
Study 8034405 — intervention group
Group type: EXPERIMENTAL
Intervention: Public communication area (functioned like a support group)
Number of subjects: 26
Study 3661107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg i.v.
Number of subjects: 40
Study 3661107 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg i.v.
Number of subjects: 40
Study 3661107 — intervention group
Group type: COMPARATOR
Intervention: Hydergine 0.9 mg i.v.
Number of subjects: 40
Study 3661107 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study 28728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercises
Number of subjects: 133
Study 28728886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study 28728886 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 133
Study 27594379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic surfactant (3mL)
Number of subjects: 40
Study 27594379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24631589 — intervention group
Group type: COMPARATOR
Intervention: LY545694 (2 doses)
Number of subjects: 0
Study 24631589 — intervention group
Group type: COMPARATOR
Intervention: LY545694 (3 doses)
Number of subjects: 0
Study 24631589 — intervention group
Group type: COMPARATOR
Intervention: LY545694 (all doses)
Number of subjects: 0
Study 23870501 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 100
Study 23870501 — intervention group
Group type: COMPARATOR
Intervention: Off site simulation (OSS)
Number of subjects: 100
Study 19930764 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-6 g beta-glucan
Number of subjects: 66
Study 19930764 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-9 g beta-glucan
Number of subjects: 66
Study 19930764 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 MJ energy-deficit diet without beta-glucan)
Number of subjects: 66
Study 19930764 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 66
Study 17512158 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA plus vouchers
Number of subjects: 43
Study 17512158 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 43
Study 16914415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous closure suture alone (Group A1)
Number of subjects: 243
Study 16914415 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture line (Group A2)
Number of subjects: 243
Study 16914415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (combined Group A1 and A2)
Number of subjects: 243
Study 16914415 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, operated by surgical residents)
Number of subjects: 243
Study 14696461 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a (4.5 million units daily for 16 weeks) plus Lamivudine (100 mg daily starting from week 5 for 48 weeks)
Number of subjects: 61
Study 14696461 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily for 48 weeks)
Number of subjects: 61
Study 10809458 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (clinical nurse specialists for symptom control and communication facilitation)
Number of subjects: 767
Study 10809458 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 767
Study 10809458 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 767
Study 8649661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent chlorhexidine solution applied with an interdental brush
Number of subjects: 33
Study 8649661 — intervention group
Group type: COMPARATOR
Intervention: 0.1 percent quinine solution (control) applied with an interdental brush
Number of subjects: 33
Study 8649661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent chlorhexidine solution
Number of subjects: 33
Study 8649661 — intervention group
Group type: COMPARATOR
Intervention: 0.1 percent quinine solution (control)
Number of subjects: 33
Study 1434863 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of fentanyl citrate
Number of subjects: 66
Study 1434863 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous administration of morphine
Number of subjects: 66
Study 2864794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg
Number of subjects: 61
Study 2864794 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine 100 mg
Number of subjects: 61
Study 30721940 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized falls prevention education (tailored education comprising patient video and workbook, structured discussion and goal setting led by trained therapist)
Number of subjects: 382
Study 30721940 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized falls prevention education
Number of subjects: 382
Study 30721940 — intervention group
Group type: COMPARATOR
Intervention: Control group (social intervention in addition to usual care)
Number of subjects: 382
Study 29405603 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (AUCB) infusion
Number of subjects: 29
Study 29405603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 26837052 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0
Study 26837052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24939813 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity CBT delivered by a fully qualified cognitive behavioural therapist
Number of subjects: 60
Study 24939813 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity guided self-help delivered by a registered nurse
Number of subjects: 60
Study 24939813 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help only without therapist support
Number of subjects: 60
Study 24939813 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control condition
Number of subjects: 60
Study 22357130 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/F HFA pMDI
Number of subjects: 568
Study 20412459 — intervention group
Group type: COMPARATOR
Intervention: Caudal levobupivacaine 0.125% (group L)
Number of subjects: 63
Study 20412459 — intervention group
Group type: COMPARATOR
Intervention: Caudal tramadol 1.5 mg.kg(‐1) (group T)
Number of subjects: 63
Study 20412459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of both (group LT)
Number of subjects: 63
Study 17680827 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAD-3/5 monoclonal anti-D IgG (MAD)
Number of subjects: 6
Study 17680827 — intervention group
Group type: EXPERIMENTAL
Intervention: rBRAD-3/5 recombinant anti-D IgG (RAD)
Number of subjects: 6
Study 15788064 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation Training Programme (ATP) plus usual care
Number of subjects: 57
Study 15788064 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 12120807 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian treatment
Number of subjects: 5
Study 12120807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9807293 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet intervention
Number of subjects: 150
Study 9807293 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet (control)
Number of subjects: 150
Study 9179964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous propolis extract NIVCRISOL administered during the cold season 1994-1995
Number of subjects: 0
Study 9179964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2712694 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert sensitization
Number of subjects: 6
Study 2712694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization
Number of subjects: 6
Study 2712694 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Number of subjects: 6
Study 2712694 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization plus medroxyprogesterone
Number of subjects: 6
Study 2712694 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 6
Study 339438 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG) 20 mg/kg/day for 10 days
Number of subjects: 45
Study 339438 — intervention group
Group type: COMPARATOR
Intervention: Human IgG 20 mg/kg/day for 10 days (Control)
Number of subjects: 45
Study 339438 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG)
Number of subjects: 45
Study 339438 — intervention group
Group type: COMPARATOR
Intervention: Human IgG (Control)
Number of subjects: 45
Study 31688793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 501
Study 31688793 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 to 7 units of red cells
Number of subjects: 501
Study 31688793 — intervention group
Group type: COMPARATOR
Intervention: Massive transfusion (MT)
Number of subjects: 501
Study 30502094 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorder
Number of subjects: 9309
Study 30502094 — intervention group
Group type: COMPARATOR
Intervention: No psychiatric disorder
Number of subjects: 9309
Study 27941526 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG) with rt‐PA
Number of subjects: 0
Study 27941526 — intervention group
Group type: COMPARATOR
Intervention: Placebo with rt‐PA
Number of subjects: 0
Study 25711509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 710
Study 25711509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the 52-week study)
Number of subjects: 710
Study 25711509 — intervention group
Group type: COMPARATOR
Intervention: Active control (in the 38-week study)
Number of subjects: 710
Study 23210916 — intervention group
Group type: COMPARATOR
Intervention: Adper Scotchbond Multi-Purpose (MP, 3M ESPE) - Control Group
Number of subjects: 60
Study 23210916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy Bond (EB, 3M ESPE)
Number of subjects: 60
Study 23210916 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Adper Easy Bond without the Vitrebond Co-polymer (EBnoCP, 3M ESPE)
Number of subjects: 60
Study 23210916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond Plus (SB, 3M ESPE)
Number of subjects: 60
Study 23210916 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Adper Single Bond Plus without CP (SBnoCP, 3M ESPE)
Number of subjects: 60
Study 21883874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PENS therapy
Number of subjects: 31
Study 21883874 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 31
Study 18638040 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft hand brace (MANU)
Number of subjects: 120
Study 18638040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist splint (CAMP TIELLE)
Number of subjects: 120
Study 18638040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 16762076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nucleotide supplementation (500 mg capsule three times a day for 56 days)
Number of subjects: 37
Study 16762076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg capsule three times a day for 56 days)
Number of subjects: 37
Study 16762076 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 37
Study 15017564 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy for Stage I‐II patients
Number of subjects: 131
Study 15017564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB) for Stage III‐IV patients
Number of subjects: 131
Study 10739900 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel picture encoding task to activate hippocampus for 2 min
Number of subjects: 0
Study 10739900 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger sequencing task to activate primary motor cortex
Number of subjects: 0
Study 9088685 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 33
Study 9088685 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 8468734 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Cisplatin + 5‐Fu) and radiation
Number of subjects: 95
Study 8468734 — intervention group
Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 95
Study 2948826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 1.5 pmol X kg‐1 X min‐1 for 30 min followed by 15 pmol X kg‐1 X min‐1 for a further 30 min
Number of subjects: 6
Study 2948826 — intervention group
Group type: COMPARATOR
Intervention: Matching vehicle infusions (control)
Number of subjects: 6
Study 3154686 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (12 to 24 mg/day orally; initial 20 mg i.v. followed by infusion of 1 to 4 mg/hour)
Number of subjects: 20
Study 30877209 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased treatment
Number of subjects: 52
Study 30877209 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged treatment
Number of subjects: 52
Study 30877209 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced treatment
Number of subjects: 52
Study 30877209 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with tocilizumab for GCA and tumor necrosis factor inhibitors for TA
Number of subjects: 52
Study 30917815 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessments and case conferencing
Number of subjects: 19
Study 29142236 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) therapy with a scoring model composed of miR-210, miR-22, and alanine aminotransferase (ALT)
Number of subjects: 112
Study 25441251 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet with 0.5 cup of soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Number of subjects: 60
Study 25441251 — intervention group
Group type: COMPARATOR
Intervention: TLC diet alone (control)
Number of subjects: 60